about
CD44, Hyaluronan, the Hematopoietic Stem Cell, and Leukemia-Initiating CellsEnhanced Control of Bladder-Associated Tumors Using Shrimp Anti-Lipopolysaccharide Factor (SALF) Antimicrobial Peptide as a Cancer Vaccine Adjuvant in Mice.PD-1/PD-L1 inhibitors in haematological malignancies: update 2017.Receptor for hyaluronan mediated motility (RHAMM/HMMR) is a novel target for promoting subcutaneous adipogenesis.Building upon the success of CART19: chimeric antigen receptor T cells for hematologic malignancies.Follicle-Stimulating Hormone Receptor Is Expressed by Most Ovarian Cancer Subtypes and Is a Safe and Effective Immunotherapeutic Target.
P2860
description
2013 nî lūn-bûn
@nan
2013 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Developing strategies in the immunotherapy of leukemias
@ast
Developing strategies in the immunotherapy of leukemias
@en
Developing strategies in the immunotherapy of leukemias
@nl
type
label
Developing strategies in the immunotherapy of leukemias
@ast
Developing strategies in the immunotherapy of leukemias
@en
Developing strategies in the immunotherapy of leukemias
@nl
prefLabel
Developing strategies in the immunotherapy of leukemias
@ast
Developing strategies in the immunotherapy of leukemias
@en
Developing strategies in the immunotherapy of leukemias
@nl
P2860
P1433
P1476
Developing strategies in the immunotherapy of leukemias
@en
P2093
Pinilla-Ibarz J
P2860
P356
10.1177/107327481302000108
P407
P577
2013-01-01T00:00:00Z